The Cass Review led directly to the ban on puberty blockers for trans young people in the UK and shaped NHS policy on clinical trials, which would only admit children from age 12. That age threshold has since shifted to 11. Families are living with the consequences now, and the distress is acute.
What the Cass Review actually did to puberty blocker access
Puberty blockers have been used safely in medicine for decades. Clinicians have prescribed them for precocious puberty, for endometriosis, for prostate conditions. In gender-affirming care, they do one thing: pause puberty, buying a young person time to think, to breathe, and to make decisions without the pressure of irreversible physical changes happening to their body. The Endocrine Society, WPATH, and most major international bodies have described their use in this context as appropriate care.
The Cass Review concluded otherwise. It recommended a highly restrictive approach to their use in gender care for young people in England, citing what it described as insufficient evidence. The ban that followed was swift and sweeping. Private prescriptions for trans youth were prohibited. NHS prescriptions became effectively unavailable, not because of a careful clinical judgement on individual cases, but because the services that would have made those judgements no longer existed. The Tavistock's Gender Identity Development Service had already been closed. The regional hubs that were supposed to replace it were years behind schedule.
Internationally, that conclusion drew significant and detailed criticism. Many gender specialists, researchers, and clinicians published formal rebuttals of the Review's methodology, its citation practices, its reliance on SEGM-linked sources, and its departure from the approaches of other high-income countries. The American Academy of Child and Adolescent Psychiatry reaffirmed its support for evidence-based gender-affirming care. Other countries, watching the UK's direction of travel, had concerns rather than consensus on their side when some followed with restrictions of their own.
But in the UK, the policy landed and held.
The NHS clinical trial: a door, or the appearance of one?
Following the ban, the NHS announced it would make puberty blockers available to trans young people only through a research trial. The framing was presented as cautious and evidence-gathering. What it meant in practice was this: access to care that other countries were still providing routinely would now only be possible inside a tightly controlled research framework, with eligibility criteria, capacity limits, and no guarantee of access.
The initial trial framework was set from age 12. That age threshold has since been lowered to 11. I understand why that change might be read as a small step in a better direction, and I also understand why families who have been waiting, sometimes for years, while a child moves through puberty they did not want, read it differently. An age threshold is not a pathway. It is a gatekeeping condition inside a system that still has nowhere near enough capacity to serve the young people who need it.
What does a clinical trial mean for a family in this situation? It means an application process. It means assessment. It means waiting. It means the very real possibility that your child will not meet the criteria, or that the site nearest to you has no places, or that the wait will outlast the window in which the intervention would have been most helpful. It means that a child who is 11 or 12 today might reach 14 or 15 still waiting, still in a puberty they are watching happen against their will.
That is not a treatment pathway, but a bureaucratic structure that performs the appearance of one.
What delay actually costs
One of the most persistent and damaging fictions in this debate is that withholding treatment is the cautious option, and that waiting is neutral. It is not. Delay has its own consequences. Unwanted pubertal changes are often distressing in ways that are real, lasting, and sometimes irreversible without later surgical intervention. The distress associated with going through the wrong puberty is not a medical abstraction. It is something I have heard described in very human terms by very many young people and their families over the years.
Worsening dysphoria, deepening depression, social withdrawal, and in the most serious cases, self-harm and suicidal ideation are all documented consequences of withholding timely care from trans young people. The question is not whether intervention carries risks, because all medical intervention does. The question is whether those risks are weighed honestly against the risks of not intervening. In the framework the Cass Review created, they were not.
I also want to say something about the families living inside this right now. The distress I hear from parents is not abstract. These are families who found their way to understanding, who did the reading, who talked with their child, who believed they were doing the right thing by seeking help, and who have then found every door in the UK either closed or so narrowly open as to be functionally shut. That is a particular kind of grief, because it sits inside a larger grief about what your child is going through, and it has nowhere obvious to go.
Why the Cass Review's influence has not loosened
The question I am asked most often, by clinicians, by families, and by people who follow this closely, is this: if the Cass Review has been so thoroughly challenged internationally, why is its grip on UK policy still so firm?
The answer is that it suited a political moment. The Review gave ministers a mechanism to restrict gender-affirming care for young people while presenting the restriction as evidence-based caution rather than ideological opposition. Once that framing was embedded, reversing it required acknowledging that the restriction had caused harm, and no government has chosen to do that. The clinical trial structure is, among other things, a political holding position: it allows officials to say that access exists while ensuring, in practice, that it remains minimal.
It is also worth being specific about the methodological criticisms that have been levelled at the Review, because they are serious ones. Concerns have been raised about the citation practices used to reach its conclusions, the sources it drew on, the exclusion of studies with positive outcomes from its synthesis, and its departure from the approach taken by comparable reviews in other countries. These are not marginal complaints. They have been raised by prominent researchers and clinicians with expertise in the field, published in detail, and not seriously rebutted by those who commissioned the original work.
None of that has changed the policy.
What this means for families in England now
If you are the parent of a trans child in England, or if you are a young trans person trying to understand what your options are, the picture is a difficult one. The NHS clinical trial is the only route that exists within the public system, and access to it is limited, slow, and uncertain. Many families who have been waiting since before the ban are still waiting.
Private prescription is banned for trans young people in the UK. That route does not exist domestically. Families who have the means and the determination have looked at options abroad, but that is not a realistic or equitable solution for most people.
What I can say is that understanding your position clearly is the first step to navigating it as well as it can be navigated. That means knowing what the trial criteria actually are, what the referral routes into it look like, how long the waits currently run, and what support exists while you wait. It also means knowing that the campaign to change this policy is active, and that many clinicians, researchers, and advocates are continuing to argue for a different approach. The situation is not static, even if it moves far more slowly than the young people caught inside it deserve.
If you are looking for medical support for a trans young person and want to understand the options available, GenderGP at gendergp.com works with families navigating this landscape and can help you understand what pathways may exist. For thinking through what this means for you or your family, Sammy is here.
If there is a topic that you would like me to cover, just let Sammy know.
Dr Helen Webberley is a gender specialist, advocate, and founder of GenderGP. She writes about trans healthcare, rights, and the lives of trans people and their families.
Comments